title: Reply: regarding the effect of dabigatran plasma concentrations.
authors.forename: Paul A
authors.initials: PA
authors.lastname: Reilly
authors.forename: Stuart J
authors.initials: SJ
authors.lastname: Connolly
authors.forename: Salim
authors.initials: S
authors.lastname: Yusuf
authors.forename: John W
authors.initials: JW
authors.lastname: Eikelboom
authors.forename: Michael D
authors.initials: MD
authors.lastname: Ezekowitz
authors.forename: Lars
authors.initials: L
authors.lastname: Wallentin
mesh_terms: D000991:Antithrombins / Q000097:blood*; D001562:Benzimidazoles / Q000097:blood*; D005260:Female; D006470:Hemorrhage / Q000453:epidemiology*; D006801:Humans; D008297:Male; D011725:Pyridines / Q000097:blood*; D020521:Stroke / Q000453:epidemiology*
chemical_list: D000991:Antithrombins; D001562:Benzimidazoles; D011725:Pyridines